George D Demetri
Overview
Explore the profile of George D Demetri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
229
Citations
21076
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hibar D, Demetri G, Peters S, Davies J, Humblet O, Maund S, et al.
PLoS One
. 2022 Aug;
17(8):e0270571.
PMID: 35939431
The clinical profiles and outcomes of patients with neurotrophic tropomyosin receptor kinase fusion-positive (NTRK+) solid tumors receiving standard of care other than tropomyosin receptor kinase inhibitor (TRKi) targeted therapy have...
12.
Neel D, Ma C, Collins N, Hornick J, Demetri G, Shulman D
Cancer Med
. 2022 Jun;
12(1):170-178.
PMID: 35670308
Background: Synovial sarcoma (SS) accounts for 8%-10% of all soft-tissue sarcomas. Clinical presentation and outcomes vary, yet discrete risk groups based on validated prognostic indices are not defined for the...
13.
Demetri G, De Braud F, Drilon A, Siena S, Patel M, Cho B, et al.
Clin Cancer Res
. 2022 May;
28(10):2196.
PMID: 35553647
No abstract available.
14.
Hemming M, Bhola P, Loycano M, Anderson J, Taddei M, Doyle L, et al.
Clin Cancer Res
. 2022 Mar;
28(11):2397-2408.
PMID: 35325095
Purpose: Leiomyosarcoma (LMS) is a neoplasm characterized by smooth muscle differentiation, complex copy-number alterations, tumor suppressor loss, and the absence of recurrent driver mutations. Clinical management for advanced disease relies...
15.
Demetri G, De Braud F, Drilon A, Siena S, Patel M, Cho B, et al.
Clin Cancer Res
. 2022 Feb;
28(7):1302-1312.
PMID: 35144967
Purpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in...
16.
Arondekar B, Duh M, Bhak R, DerSarkissian M, Huynh L, Wang K, et al.
Clin Cancer Res
. 2021 Oct;
28(1):27-35.
PMID: 34667027
Real-world evidence (RWE) has garnered great interest to support registration of new therapies and label expansions by the United States Food and Drug Administration (FDA). Currently, practical insights on the...
17.
Garcia-Valverde A, Rosell J, Sayols S, Gomez-Peregrina D, Pilco-Janeta D, Olivares-Rivas I, et al.
Oncogene
. 2021 Oct;
40(48):6614-6626.
PMID: 34621020
KIT/PDGFRA oncogenic tyrosine kinase signaling is the central oncogenic event in most gastrointestinal stromal tumors (GIST), which are human malignant mesenchymal neoplasms that often feature myogenic differentiation. Although targeted inhibition...
18.
Hofheinz R, Bruix J, Demetri G, Grothey A, Marian M, Bartsch J, et al.
Cancer Manag Res
. 2021 Jul;
13:5523-5533.
PMID: 34285574
Purpose: The efficacy and safety of regorafenib have been demonstrated in phase 3 trials for multiple tumor types, including metastatic colorectal cancer (mCRC) (CORRECT [NCT01103323]; CONCUR [NCT01584830]), advanced gastrointestinal stromal...
19.
Bauer S, Demetri G, Halilovic E, Dummer R, Meille C, Tan D, et al.
Br J Cancer
. 2021 Jun;
125(5):687-698.
PMID: 34140638
Background: CGM097 inhibits the p53-HDM2 interaction leading to downstream p53 activation. Preclinical in vivo studies support clinical exploration while providing preliminary evidence for dosing regimens. This first-in-human phase I study...
20.
Jones R, Herzog T, Patel S, von Mehren M, Schuetze S, Van Tine B, et al.
Cancer Med
. 2021 May;
10(11):3565-3574.
PMID: 33960681
Background: As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease...